In addition, we investigated the interaction of S100A10 with therapeutic agents for LIHC, and the findings demonstrated that S100A10 has a substantial binding affinity to these drugs, underscoring its potential as a therapeutic target for liver cancer (Figure 7H). This evidence concerns the gene S100A10 and liver cancer.